Operating Income (Loss) in USD of Lexaria Bioscience Corp. from Q2 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Lexaria Bioscience Corp. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2013 to Q3 2025.
  • Lexaria Bioscience Corp. Operating Income (Loss) for the quarter ending August 31, 2025 was -$2.69M, a 22% decline year-over-year.
  • Lexaria Bioscience Corp. Operating Income (Loss) for the twelve months ending August 31, 2025 was -$11.9M, a 107% decline year-over-year.
  • Lexaria Bioscience Corp. annual Operating Income (Loss) for 2025 was -$11.9M, a 107% decline from 2024.
  • Lexaria Bioscience Corp. annual Operating Income (Loss) for 2024 was -$5.75M, a 12% increase from 2023.
  • Lexaria Bioscience Corp. annual Operating Income (Loss) for 2023 was -$6.53M, a 1.28% increase from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Lexaria Bioscience Corp. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$11.9M -$2.69M -$486K -22% Jun 1, 2025 Aug 31, 2025 10-K 2025-11-28
Q2 2025 -$11.4M -$3.75M -$2.01M -115% Mar 1, 2025 May 31, 2025 10-Q 2025-07-14
Q1 2025 -$9.39M -$2.75M -$2.08M -312% Dec 1, 2024 Feb 28, 2025 10-Q 2025-04-14
Q4 2024 -$7.3M -$2.69M -$1.55M -136% Sep 1, 2024 Nov 30, 2024 10-Q 2025-01-10
Q3 2024 -$5.75M -$2.2M -$1.09M -97.7% Jun 1, 2024 Aug 31, 2024 10-K 2025-11-28
Q2 2024 -$4.66M -$1.74M +$658K +27.4% Mar 1, 2024 May 31, 2024 10-Q 2025-07-14
Q1 2024 -$5.32M -$668K +$656K +49.5% Dec 1, 2023 Feb 29, 2024 10-Q 2025-04-14
Q4 2023 -$5.98M -$1.14M +$556K +32.8% Sep 1, 2023 Nov 30, 2023 10-Q 2025-01-10
Q3 2023 -$6.53M -$1.11M Jun 1, 2023 Aug 31, 2023 10-K 2024-11-26
Q2 2023 -$2.4M +$17.5K +0.72% Mar 1, 2023 May 31, 2023 10-Q 2024-07-12
Q1 2023 -$1.32M Dec 1, 2022 Feb 28, 2023 10-Q 2024-04-09
Q4 2022 -$1.7M Sep 1, 2022 Nov 30, 2022 10-Q 2024-01-12
Q2 2022 -$2.42M +$148K +5.78% Mar 1, 2022 May 31, 2022 10-Q 2022-07-14
Q2 2021 -$2.57M Mar 1, 2021 May 31, 2021 10-Q 2022-07-14
Q4 2017 -$579K -$178K -44.5% Sep 1, 2017 Nov 30, 2017 10-Q 2018-01-12
Q4 2016 -$1.27M -$401K +$11.2K +2.72% Sep 1, 2016 Nov 30, 2016 10-Q 2018-01-12
Q3 2016 -$1.28M -$327K +$289K +46.9% Jun 1, 2016 Aug 31, 2016 10-K 2016-11-29
Q2 2016 -$1.57M -$264K +$247K +48.3% Mar 1, 2016 May 31, 2016 10-Q 2016-07-13
Q1 2016 -$1.81M -$275K +$184K +40.1% Dec 1, 2015 Feb 29, 2016 10-Q 2016-04-13
Q4 2015 -$2M -$412K -$13.7K -3.43% Sep 1, 2015 Nov 30, 2015 10-Q 2016-01-08
Q3 2015 -$1.98M -$616K Jun 1, 2015 Aug 31, 2015 10-K 2016-11-29
Q2 2015 -$511K +$56.9K +10% Mar 1, 2015 May 31, 2015 10-Q 2016-07-13
Q1 2015 -$459K Nov 29, 2014 Feb 28, 2015 10-Q 2016-04-13
Q4 2014 -$398K Sep 1, 2014 Nov 30, 2014 10-Q 2016-01-08
Q2 2014 -$568K -$510K -885% May 1, 2014 Jul 31, 2014 10-Q 2014-11-14
Q2 2013 -$57.7K May 1, 2013 Jul 31, 2013 10-Q 2014-11-14

Lexaria Bioscience Corp. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 -$11.9M -$6.13M -107% Sep 1, 2024 Aug 31, 2025 10-K 2025-11-28
2024 -$5.75M +$781K +12% Sep 1, 2023 Aug 31, 2024 10-K 2025-11-28
2023 -$6.53M +$85K +1.28% Sep 1, 2022 Aug 31, 2023 10-K 2024-11-26
2022 -$6.62M -$932K -16.4% Sep 1, 2021 Aug 31, 2022 10-K 2023-11-20
2021 -$5.69M Sep 1, 2020 Aug 31, 2021 10-K 2022-11-28
2016 -$1.28M +$706K +35.6% Sep 1, 2015 Aug 31, 2016 10-K 2016-11-29
2015 -$1.98M -$424K -27.2% Sep 1, 2014 Aug 31, 2015 10-K 2016-11-29
2014 -$1.56M Sep 1, 2013 Aug 31, 2014 10-K 2015-11-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.